New York Times: A cancer is overtaking our space agency: the routine acquiescence to immense cost increases in projects. Unmistakable new indications of this illness surfaced last month with NASA's decision to spend at least $100 million more on its poorly-managed, now-over-$2 billion Mars Science Laboratory. This decision to go forward with the project, a robotic rover, was made even though it has tripled in cost since its inception, it is behind schedule, there is no firm estimate of the final cost, and NASA hasn't disclosed the collateral damage inflicted on other programs and activities that depend on NASA's limited science budget.